{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:51:09Z","timestamp":1786989069025,"version":"build-2736575974"},"reference-count":131,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,8]],"date-time":"2022-06-08T00:00:00Z","timestamp":1654646400000},"content-version":"vor","delay-in-days":1499,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100009647","name":"Ministry of Health","doi-asserted-by":"publisher","award":["DRO-FNOs\/2017"],"award-info":[{"award-number":["DRO-FNOs\/2017"]}],"id":[{"id":"10.13039\/100009647","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009647","name":"Ministry of Health","doi-asserted-by":"publisher","award":["17-30089A"],"award-info":[{"award-number":["17-30089A"]}],"id":[{"id":"10.13039\/100009647","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Institutional Development Plan of University of Ostrava","award":["IRP201550"],"award-info":[{"award-number":["IRP201550"]}]},{"name":"Strengthening International Cooperation in Science, Research and Education","award":["01211\/2016\/RRC"],"award-info":[{"award-number":["01211\/2016\/RRC"]}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","exphem.org","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Hematology"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1016\/j.exphem.2018.02.002","type":"journal-article","created":{"date-parts":[[2018,3,2]],"date-time":"2018-03-02T09:16:32Z","timestamp":1519982192000},"page":"10-25","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":90,"special_numbering":"C","title":["Venetoclax: A new wave in hematooncology"],"prefix":"10.1016","volume":"61","author":[{"given":"Jana","family":"Mihalyova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomas","family":"Jelinek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katerina","family":"Growkova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matous","family":"Hrdinka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michal","family":"Simicek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roman","family":"Hajek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.exphem.2018.02.002_bib0010","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1128\/IAI.73.4.1907-1916.2005","article-title":"Apoptosis, pyroptosis, and necrosis: mechanistic description of dead and dying eukaryotic cells","volume":"73","author":"Fink","year":"2005","journal-title":"Infect Immun"},{"key":"10.1016\/j.exphem.2018.02.002_bib0015","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/bjc.1972.33","article-title":"Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics","volume":"26","author":"Kerr","year":"1972","journal-title":"Br J Cancer"},{"key":"10.1016\/j.exphem.2018.02.002_bib0020","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1038\/nrc883","article-title":"The Bcl2 family: regulators of the cellular life-or-death switch","volume":"2","author":"Cory","year":"2002","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.exphem.2018.02.002_bib0025","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0092-8674(00)81683-9","article-title":"The hallmarks of cancer","volume":"100","author":"Hanahan","year":"2000","journal-title":"Cell"},{"key":"10.1016\/j.exphem.2018.02.002_bib0030","doi-asserted-by":"crossref","first-page":"14871","DOI":"10.1073\/pnas.96.26.14871","article-title":"Activation of Fas by FasL induces apoptosis by a mechanism that cannot be blocked by Bcl-2 or Bcl-xL","volume":"96","author":"Huang","year":"1999","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.exphem.2018.02.002_bib0035","doi-asserted-by":"crossref","first-page":"6136","DOI":"10.1002\/j.1460-2075.1995.tb00304.x","article-title":"Bcl-2 and Fas\/APO-1 regulate distinct pathways to lymphocyte apoptosis","volume":"14","author":"Strasser","year":"1995","journal-title":"EMBO J"},{"key":"10.1016\/j.exphem.2018.02.002_bib0040","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1096\/fj.08-111005","article-title":"Life and death by death receptors","volume":"23","author":"Guicciardi","year":"2009","journal-title":"FASEB J"},{"key":"10.1016\/j.exphem.2018.02.002_bib0045","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.molcel.2004.12.030","article-title":"Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function","volume":"17","author":"Chen","year":"2005","journal-title":"Mol Cell"},{"key":"10.1016\/j.exphem.2018.02.002_bib0050","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S1535-6108(02)00128-9","article-title":"BH3 domains: intracellular death-ligands critical for initiating apoptosis","volume":"2","author":"Chittenden","year":"2002","journal-title":"Cancer Cell"},{"key":"10.1016\/j.exphem.2018.02.002_bib0055","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/nrm3722","article-title":"Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy","volume":"15","author":"Czabotar","year":"2014","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.exphem.2018.02.002_bib0060","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0092-8674(00)00187-2","article-title":"BH3-Only proteins-essential initiators of apoptotic cell death","volume":"103","author":"Huang","year":"2000","journal-title":"Cell"},{"key":"10.1016\/j.exphem.2018.02.002_bib0065","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1101\/gad.1304105","article-title":"Proapoptotic Bak is sequestered by Mcl-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins","volume":"19","author":"Willis","year":"2005","journal-title":"Genes Dev"},{"key":"10.1016\/j.exphem.2018.02.002_bib0070","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1126\/science.1133289","article-title":"Apoptosis initiated when BH3 ligands engage multiple Bcl-2 homologs, not Bax or Bak","volume":"315","author":"Willis","year":"2007","journal-title":"Science"},{"key":"10.1016\/j.exphem.2018.02.002_bib0075","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1002\/(SICI)1097-0215(19960422)69:2<100::AID-IJC5>3.0.CO;2-4","article-title":"bcl-2\/bax mRNA expression ratio as prognostic factor in low-grade urinary bladder cancer","volume":"69","author":"Gazzaniga","year":"1996","journal-title":"Int J Cancer"},{"key":"10.1016\/j.exphem.2018.02.002_bib0080","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1002\/path.1711770206","article-title":"Expression of bcl-2 oncogene protein is prevalent in small cell lung carcinomas","volume":"177","author":"Jiang","year":"1995","journal-title":"J Pathol"},{"key":"10.1016\/j.exphem.2018.02.002_bib0085","first-page":"1191","article-title":"Bcl-2 protein expression and long-term survival in breast cancer","volume":"145","author":"Joensuu","year":"1994","journal-title":"Am J Pathol"},{"key":"10.1016\/j.exphem.2018.02.002_bib0090","doi-asserted-by":"crossref","first-page":"15524","DOI":"10.1073\/pnas.242606799","article-title":"Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia","volume":"99","author":"Calin","year":"2002","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.exphem.2018.02.002_bib0095","doi-asserted-by":"crossref","first-page":"5269","DOI":"10.1182\/blood.V87.12.5269.bloodjournal87125269","article-title":"DNA copy number changes in diffuse large B-cell lymphoma\u2013comparative genomic hybridization study","volume":"87","author":"Monni","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2018.02.002_bib0100","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/cdd.2014.87","article-title":"Role of miR-15\/16 in CLL","volume":"22","author":"Pekarsky","year":"2015","journal-title":"Cell Death Differ"},{"key":"10.1016\/j.exphem.2018.02.002_bib0105","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1126\/science.6093263","article-title":"Cloning of the chromosome breakpoint of neoplastic B cells with the t (14;18) chromosome translocation","volume":"226","author":"Tsujimoto","year":"1984","journal-title":"Science"},{"key":"10.1016\/j.exphem.2018.02.002_bib0110","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1056\/NEJM200012283432602","article-title":"Genomic aberrations and survival in chronic lymphocytic leukemia","volume":"343","author":"D\u00f6hner","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.exphem.2018.02.002_bib0115","doi-asserted-by":"crossref","first-page":"4783","DOI":"10.1182\/blood-2012-04-423517","article-title":"High-resolution genomic profiling of chronic lymphocytic leukemia reveals new recurrent genomic alterations","volume":"120","author":"Edelmann","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2018.02.002_bib0120","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/0092-8674(95)90412-3","article-title":"Tumor suppressor p53 is a direct transcriptional activator of the human bax gene","volume":"80","author":"Toshiyuki","year":"1995","journal-title":"Cell"},{"key":"10.1016\/j.exphem.2018.02.002_bib0125","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/S1097-2765(01)00214-3","article-title":"PUMA, a novel proapoptotic gene, is induced by p53","volume":"7","author":"Nakano","year":"2001","journal-title":"Mol Cell"},{"key":"10.1016\/j.exphem.2018.02.002_bib0130","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1073\/pnas.2627984100","article-title":"PUMA mediates the apoptotic response to p53 in colorectal cancer cells","volume":"100","author":"Yu","year":"2003","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.exphem.2018.02.002_bib0135","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0014-5793(04)00059-6","article-title":"Defining the p53 DNA-binding domain\/Bcl-x (L)-binding interface using NMR","volume":"559","author":"Petros","year":"2004","journal-title":"FEBS Lett"},{"key":"10.1016\/j.exphem.2018.02.002_bib0140","doi-asserted-by":"crossref","first-page":"a001883","DOI":"10.1101\/cshperspect.a001883","article-title":"Tumor suppressive functions of p53","volume":"1","author":"Zilfou","year":"2009","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"10.1016\/j.exphem.2018.02.002_bib0145","doi-asserted-by":"crossref","first-page":"10890","DOI":"10.1074\/jbc.M513655200","article-title":"Specific requirement for Bax, not Bak, in Myc-induced apoptosis and tumor suppression in vivo","volume":"281","author":"Dansen","year":"2006","journal-title":"J Biol Chem"},{"key":"10.1016\/j.exphem.2018.02.002_bib0150","doi-asserted-by":"crossref","first-page":"6164","DOI":"10.1073\/pnas.0401471101","article-title":"Bim is a suppressor of Myc-induced mouse B cell leukemia","volume":"101","author":"Egle","year":"2004","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.exphem.2018.02.002_bib0155","doi-asserted-by":"crossref","first-page":"19488","DOI":"10.1073\/pnas.0708380104","article-title":"Tumor cell-selective regulation of NOXA by c-MYC in response to proteasome inhibition","volume":"104","author":"Nikiforov","year":"2007","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.exphem.2018.02.002_bib0160","doi-asserted-by":"crossref","first-page":"6462","DOI":"10.1038\/onc.2008.312","article-title":"Apoptotic signaling by c-MYC","volume":"27","author":"Hoffman","year":"2008","journal-title":"Oncogene"},{"key":"10.1016\/j.exphem.2018.02.002_bib0165","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.semcancer.2006.07.011","article-title":"The Oscar-worthy role of Myc in apoptosis","volume":"16","author":"Meyer","year":"2006","journal-title":"Semin Cancer Biol"},{"key":"10.1016\/j.exphem.2018.02.002_bib0170","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.4161\/cc.6.20.4917","article-title":"c-Myc blazing a trail of death: coupling of the mitochondrial and death receptor apoptosis pathways by c-Myc","volume":"6","author":"Nieminen","year":"2007","journal-title":"Cell Cycle"},{"key":"10.1016\/j.exphem.2018.02.002_bib0175","doi-asserted-by":"crossref","first-page":"9007","DOI":"10.1038\/sj.onc.1207261","article-title":"Myc pathways provoking cell suicide and cancer","volume":"22","author":"Nilsson","year":"2003","journal-title":"Oncogene"},{"key":"10.1016\/j.exphem.2018.02.002_bib0180","doi-asserted-by":"crossref","first-page":"2826","DOI":"10.3109\/10428194.2015.1030638","article-title":"A phase 2 study of the BH3 mimetic BCL2 inhibitor navitoclax (ABT-263) with or without rituximab, in previously untreated B-cell chronic lymphocytic leukemia","volume":"56","author":"Kipps","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.exphem.2018.02.002_bib0185","doi-asserted-by":"crossref","first-page":"19512","DOI":"10.1073\/pnas.0709443104","article-title":"Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis","volume":"104","author":"Nguyen","year":"2007","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.exphem.2018.02.002_bib0190","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1186\/s12885-015-1582-5","article-title":"Obatoclax is a direct and potent antagonist of membrane-restricted Mcl-1 and is synthetic lethal with treatment that induces Bim","volume":"15","author":"Nguyen","year":"2015","journal-title":"BMC Cancer"},{"key":"10.1016\/j.exphem.2018.02.002_bib0195","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.4161\/cbt.7.9.6430","article-title":"Apogossypolone, a nonpeptidic small molecule inhibitor targeting Bcl-2 family proteins, effectively inhibits growth of diffuse large cell lymphoma cells in vitro and in vivo","volume":"7","author":"Sun","year":"2008","journal-title":"Cancer Biol Ther"},{"key":"10.1016\/j.exphem.2018.02.002_bib0200","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1200\/JCO.2011.34.7898","article-title":"Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease","volume":"30","author":"Roberts","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.exphem.2018.02.002_bib0205","doi-asserted-by":"crossref","first-page":"3421","DOI":"10.1158\/0008-5472.CAN-07-5836","article-title":"ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor","volume":"68","author":"Tse","year":"2008","journal-title":"Cancer Res"},{"key":"10.1016\/j.exphem.2018.02.002_bib0210","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/S1470-2045(10)70261-8","article-title":"Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity","volume":"11","author":"Wilson","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.exphem.2018.02.002_bib0215","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nm.3048","article-title":"ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets","volume":"19","author":"Souers","year":"2013","journal-title":"Nat Med"},{"key":"10.1016\/j.exphem.2018.02.002_bib0220","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.ccr.2006.10.006","article-title":"Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia","volume":"10","author":"Konopleva","year":"2006","journal-title":"Cancer Cell"},{"key":"10.1016\/j.exphem.2018.02.002_bib0225","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1513257","article-title":"Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia","volume":"374","author":"Roberts","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.exphem.2018.02.002_bib0230","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1002\/jcph.821","article-title":"Pharmacokinetics of venetoclax, a novel BCL-2 inhibitor, in patients with relapsed or refractory chronic lymphocytic leukemia or non-Hodgkin lymphoma","volume":"57","author":"Salem","year":"2017","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.exphem.2018.02.002_bib0235","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1002\/jcph.741","article-title":"Effect of low- and high-fat meals on the pharmacokinetics of venetoclax, a selective first-in-class BCL-2 inhibitor","volume":"56","author":"Salem","year":"2016","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.exphem.2018.02.002_bib0240","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1002\/jcph.730","article-title":"Evaluation of rifampin's transporter inhibitory and CYP3A inductive effects on the pharmacokinetics of venetoclax, a BCL-2 inhibitor: results of a single- and multiple-dose study","volume":"56","author":"Agarwal","year":"2016","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.exphem.2018.02.002_bib0245","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1007\/s40262-016-0453-9","article-title":"Impact of venetoclax exposure on clinical efficacy and safety in patients with relapsed or refractory chronic lymphocytic leukemia","volume":"56","author":"Freise","year":"2017","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.exphem.2018.02.002_bib0250","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1136\/jcp.51.5.364","article-title":"Levels of expression of CD19 and CD20 in chronic B cell leukaemias","volume":"51","author":"Ginaldi","year":"1998","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.exphem.2018.02.002_bib0255","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1182\/blood.V82.6.1820.1820","article-title":"bcl-2 gene hypomethylation and high-level expression in B-cell chronic lymphocytic leukemia","volume":"82","author":"Hanada","year":"1993","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2018.02.002_bib0260","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1200\/JCO.2006.07.1191","article-title":"Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia","volume":"25","author":"O'Brien","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.exphem.2018.02.002_bib0265","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1182\/blood.V79.11.2981.2981","article-title":"Growth- and differentiation-associated expression of bcl-2 in B-chronic lymphocytic leukemia cells","volume":"79","author":"Schena","year":"1992","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2018.02.002_bib0270","doi-asserted-by":"crossref","first-page":"3682","DOI":"10.1182\/blood.V83.12.3682.3682","article-title":"BCL2 translocations in leukemias of mature B cells","volume":"83","author":"Dyer","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2018.02.002_bib0275","doi-asserted-by":"crossref","first-page":"13944","DOI":"10.1073\/pnas.0506654102","article-title":"miR-15 and miR-16 induce apoptosis by targeting BCL2","volume":"102","author":"Cimmino","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.exphem.2018.02.002_bib0280","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/S1470-2045(16)30019-5","article-title":"Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study","volume":"17","author":"Stilgenbauer","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.exphem.2018.02.002_bib0285","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1182\/blood.V128.22.637.637","article-title":"Venetoclax (VEN) monotherapy for patients with chronic lymphocytic leukemia (CLL) who relapsed after or were refractory to ibrutinib or idelalisib","volume":"128","author":"Jones","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2018.02.002_bib0290","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S1470-2045(17)30012-8","article-title":"Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study","volume":"18","author":"Seymour","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.exphem.2018.02.002_bib0295","author":"Rogers"},{"key":"10.1016\/j.exphem.2018.02.002_bib0300","doi-asserted-by":"crossref","first-page":"4393","DOI":"10.1182\/blood.V128.22.4393.4393","article-title":"Phase Ib study (GO28440) of venetoclax with bendamustine\/rituximab or bendamustine\/obinutuzumab in patients with relapsed\/refractory or previously untreated chronic lymphocytic leukemia","volume":"128","author":"Stilgenbauer","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2018.02.002_bib0305","author":"Cramer"},{"key":"10.1016\/j.exphem.2018.02.002_bib0310","author":"Fischer"},{"key":"10.1016\/j.exphem.2018.02.002_bib0315","first-page":"428","article-title":"Initial results of ibrutinib plus venetoclax in relapsed, refractory CLL (Bloodwise TAP CLARITY Study): high rates of overall response, complete remission and MRD eradication after 6 months of combination therapy","volume":"130","author":"Hillmen","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2018.02.002_bib0320","first-page":"429","article-title":"Combined venetoclax and ibrutinib for patients with previously untreated high-risk CLL, and relapsed\/refractory CLL: a phase II trial","volume":"130","author":"Jain","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2018.02.002_bib0325","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2018.02.002_bib0330","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1016\/S0002-9440(10)65710-0","article-title":"Differential expression of cyclin D1 in mantle cell lymphoma and other non-Hodgkin's lymphomas","volume":"153","author":"Ives Aguilera","year":"1998","journal-title":"Am J Pathol"},{"key":"10.1016\/j.exphem.2018.02.002_bib0335","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/j.1365-2141.1991.tb08582.x","article-title":"Non-Hodgkin's lymphomas with t (11;14) (q13;q32): a subset of mantle zone\/intermediate lymphocytic lymphoma?","volume":"77","author":"Leroux","year":"1991","journal-title":"Br J Haematol"},{"key":"10.1016\/j.exphem.2018.02.002_bib0340","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1111\/j.1365-2141.1992.tb08209.x","article-title":"Chromosome 11q rearrangements in B non-Hodgkin's lymphoma","volume":"81","author":"Vandenberghe","year":"1992","journal-title":"Br J Haematol"},{"key":"10.1016\/j.exphem.2018.02.002_bib0345","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1182\/blood-2009-02-179739","article-title":"How I treat mantle cell lymphoma","volume":"114","author":"Ghielmini","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2018.02.002_bib0350","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/(SICI)1098-2264(200003)27:3<285::AID-GCC9>3.0.CO;2-M","article-title":"t (11;14)-positive mantle cell lymphomas exhibit complex karyotypes and share similarities with B-cell chronic lymphocytic leukemia","volume":"27","author":"Bentz","year":"2000","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.exphem.2018.02.002_bib0355","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1038\/nature03845","article-title":"Evasion of the p53 tumour surveillance network by tumour-derived MYC mutants","volume":"436","author":"Hemann","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.exphem.2018.02.002_bib0360","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1200\/JCO.2016.70.4320","article-title":"Phase I first-in-human study of venetoclax in patients with relapsed or refractory non-Hodgkin lymphoma","volume":"35","author":"Davids","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.exphem.2018.02.002_bib0365","doi-asserted-by":"crossref","first-page":"7520","DOI":"10.1200\/JCO.2017.35.15_suppl.7520","article-title":"Combination ibrutinib (Ibr) and venetoclax (Ven) for the treatment of mantle cell lymphoma (MCL): primary endpoint assessment of the phase 2 AIM study","volume":"35","author":"Tam","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.exphem.2018.02.002_bib0370","doi-asserted-by":"crossref","first-page":"5019","DOI":"10.1182\/blood-2011-01-293050","article-title":"The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications","volume":"117","author":"Campo","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2018.02.002_bib0375","doi-asserted-by":"crossref","first-page":"3152","DOI":"10.1182\/blood.V92.9.3152","article-title":"Clinical relevance of BCL2, BCL6, and MYC rearrangements in diffuse large B-cell lymphoma","volume":"92","author":"Kramer","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2018.02.002_bib0380","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1097\/PAP.0b013e3182a289f2","article-title":"MYC\/BCL2 double-hit high-grade B-cell lymphoma","volume":"20","author":"Li","year":"2013","journal-title":"Adv Anat Pathol"},{"key":"10.1016\/j.exphem.2018.02.002_bib0385","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.ccr.2007.08.011","article-title":"A signaling pathway mediating downregulation of BCL6 in germinal center B cells is blocked by BCL6 gene alterations in B cell lymphoma","volume":"12","author":"Saito","year":"2007","journal-title":"Cancer Cell"},{"key":"10.1016\/j.exphem.2018.02.002_bib0390","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1182\/blood-2010-09-297879","article-title":"Double-hit B-cell lymphomas","volume":"117","author":"Aukema","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2018.02.002_bib0395","doi-asserted-by":"crossref","first-page":"3032","DOI":"10.1182\/blood.V128.22.3032.3032","article-title":"Results of a phase Ib Study of venetoclax plus R- or G-CHOP in patients with B-cell non-Hodgkin lymphoma","volume":"128","author":"Zelenetz","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2018.02.002_bib0400","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1182\/blood-2015-06-649905","article-title":"Cell of origin of transformed follicular lymphoma","volume":"126","author":"Kridel","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2018.02.002_bib0405","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1200\/JCO.2010.32.7577","article-title":"Transformation of indolent B-cell lymphomas","volume":"29","author":"Montoto","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.exphem.2018.02.002_bib0410","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1093\/ajcp\/103.4.472","article-title":"Comparison of cytogenetic analysis, southern analysis, and polymerase chain reaction for the detection of t (14; 18) in follicular lymphoma","volume":"103","author":"Horsman","year":"1995","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.exphem.2018.02.002_bib0415","doi-asserted-by":"crossref","first-page":"8886","DOI":"10.1073\/pnas.132253599","article-title":"Transformation of follicular lymphoma to diffuse large-cell lymphoma: alternative patterns with increased or decreased expression of c-myc and its regulated genes","volume":"99","author":"Lossos","year":"2002","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.exphem.2018.02.002_bib0420","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/modpathol.2011.213","article-title":"Genomic analysis of marginal zone and lymphoplasmacytic lymphomas identified common and disease-specific abnormalities","volume":"25","author":"Braggio","year":"2012","journal-title":"Mod Pathol"},{"key":"10.1016\/j.exphem.2018.02.002_bib0425","series-title":"Flow cytometry of hematological malignancies","author":"Ortolani","year":"2011"},{"key":"10.1016\/j.exphem.2018.02.002_bib0430","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1182\/blood-2013-09-525808","article-title":"The genomic landscape of Waldenstr\u00f6m macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis","volume":"123","author":"Hunter","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2018.02.002_bib0435","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1056\/NEJMoa1200710","article-title":"MYD88 L265P somatic mutation in Waldenstr\u00f6m's macroglobulinemia","volume":"367","author":"Treon","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.exphem.2018.02.002_bib0440","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1182\/blood-2006-02-005488","article-title":"Gene-expression profiling of Waldenstr\u00f6m macroglobulinemia reveals a phenotype more similar to chronic lymphocytic leukemia than multiple myeloma","volume":"108","author":"Chng","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2018.02.002_bib0445","doi-asserted-by":"crossref","first-page":"3174","DOI":"10.1182\/blood.V110.11.3174.3174","article-title":"Comprehensive molecular characterization of malignant and microenvironmental cells in Waldenstrom's macroglobulinemia by gene expression profiling","volume":"110","author":"Hatjiharissi","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2018.02.002_bib0450","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1111\/bjh.13278","article-title":"The BCL2 antagonist ABT-199 triggers apoptosis, and augments ibrutinib and idelalisib mediated cytotoxicity in CXCR4 wild-type and CXCR4 WHIM mutated Waldenstrom macroglobulinaemia cells","volume":"170","author":"Cao","year":"2015","journal-title":"Br J Haematol"},{"key":"10.1016\/j.exphem.2018.02.002_bib0455","doi-asserted-by":"crossref","first-page":"e1254856","DOI":"10.1080\/2162402X.2016.1254856","article-title":"PD-1\/PD-L1 inhibitors in multiple myeloma: the present and the future","volume":"5","author":"Jelinek","year":"2016","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.exphem.2018.02.002_bib0460","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.blre.2015.08.004","article-title":"Monoclonal antibodies: a new era in the treatment of multiple myeloma","volume":"30","author":"Jelinek","year":"2016","journal-title":"Blood Rev"},{"key":"10.1016\/j.exphem.2018.02.002_bib0465","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1038\/leu.2015.184","article-title":"BH3 profiling identifies heterogeneous dependency on Bcl-2 family members in multiple myeloma and predicts sensitivity to BH3 mimetics","volume":"30","author":"Touzeau","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2018.02.002_bib0470","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1038\/leu.2013.216","article-title":"The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t (11;14) multiple myeloma","volume":"28","author":"Touzeau","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2018.02.002_bib0475","doi-asserted-by":"crossref","first-page":"e112","DOI":"10.3324\/haematol.2016.160408","article-title":"Deep and sustained response after venetoclax therapy in a patient with very advanced refractory myeloma with translocation t (11;14)","volume":"102","author":"Touzeau","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.exphem.2018.02.002_bib0480","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1038\/leu.2015.350","article-title":"Dexamethasone treatment promotes Bcl-2 dependence in multiple myeloma resulting in sensitivity to venetoclax","volume":"30","author":"Matulis","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2018.02.002_bib0485","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1182\/blood.V128.22.488.488","article-title":"Venetoclax monotherapy for relapsed\/refractory multiple myeloma: safety and efficacy results from a phase I study","volume":"128","author":"Kumar","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2018.02.002_bib0490","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1182\/blood.V128.22.975.975","article-title":"Venetoclax combined with bortezomib and dexamethasone for patients with relapsed\/refractory multiple myeloma","volume":"128","author":"Moreau","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2018.02.002_bib0495","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/imm.12788","article-title":"PD-1\/PD-L1 inhibitors in haematological malignancies: update 2017","volume":"152","author":"Jelinek","year":"2017","journal-title":"Immunology"},{"key":"10.1016\/j.exphem.2018.02.002_bib0500","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","article-title":"Genomic classification and prognosis in acute myeloid leukemia","volume":"374","author":"Papaemmanuil","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.exphem.2018.02.002_bib0505","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/s13045-017-0463-6","article-title":"Emerging therapies for acute myeloid leukemia","volume":"10","author":"Saygin","year":"2017","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.exphem.2018.02.002_bib0510","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1126\/science.1106114","article-title":"Obligate role of anti-apoptotic MCL-1 in the survival of hematopoietic stem cells","volume":"307","author":"Opferman","year":"2005","journal-title":"Science"},{"key":"10.1016\/j.exphem.2018.02.002_bib0515","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1158\/2159-8290.CD-13-0609","article-title":"Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia","volume":"4","author":"Pan","year":"2014","journal-title":"Cancer Discov"},{"key":"10.1016\/j.exphem.2018.02.002_bib0520","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1038\/nm.3788","article-title":"Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia","volume":"21","author":"Chan","year":"2015","journal-title":"Nat Med"},{"key":"10.1016\/j.exphem.2018.02.002_bib0525","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1158\/2159-8290.CD-16-0313","article-title":"Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia","volume":"6","author":"Konopleva","year":"2016","journal-title":"Cancer Discov"},{"key":"10.1016\/j.exphem.2018.02.002_bib0530","first-page":"2628","article-title":"Updated safety and efficacy of venetoclax with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia","volume":"130","author":"DiNardo","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2018.02.002_bib0535","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1182\/blood.V130.Suppl_1.890.890","article-title":"Phase 1\/2 study of venetoclax with low-dose cytarabine in treatment-naive, elderly patients with acute myeloid leukemia unfit for intensive chemotherapy: 1-year outcomes","volume":"130","author":"Wei","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2018.02.002_bib0540","first-page":"418","article-title":"BCL2 expression identifies a population with unmet medical need in previously untreated (1L) patients with DLBCL","volume":"130","author":"Szafer-Glusman","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2018.02.002_bib0545","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1182\/blood-2016-12-759621","article-title":"BCL2 expression in DLBCL: reappraisal of immunohistochemistry with new criteria for therapeutic biomarker evaluation","volume":"130","author":"Tsuyama","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2018.02.002_bib0550","doi-asserted-by":"crossref","first-page":"2767","DOI":"10.1200\/JCO.2007.15.0177","article-title":"Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review","volume":"26","author":"Coiffier","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.exphem.2018.02.002_bib0555","doi-asserted-by":"crossref","first-page":"279ra40","DOI":"10.1126\/scitranslmed.aaa4642","article-title":"Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy","volume":"7","author":"Leverson","year":"2015","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.exphem.2018.02.002_bib0560","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1084\/jem.189.11.1691","article-title":"bcl-x prevents apoptotic cell death of both primitive and definitive erythrocytes at the end of maturation","volume":"189","author":"Motoyama","year":"1999","journal-title":"J Exp Med"},{"key":"10.1016\/j.exphem.2018.02.002_bib0565","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0092-8674(00)81013-2","article-title":"Fetal anemia and apoptosis of red cell progenitors in Stat5a-\/-5b-\/- mice: a direct role for Stat5 in Bcl-X (L) induction","volume":"98","author":"Socolovsky","year":"1999","journal-title":"Cell"},{"key":"10.1016\/j.exphem.2018.02.002_bib0570","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1084\/jem.192.5.647","article-title":"FAS ligand, Bcl-2, granulocyte colony-stimulating factor, and p38 mitogen-activated protein kinase","volume":"192","author":"Villunger","year":"2000","journal-title":"J Exp Med"},{"key":"10.1016\/j.exphem.2018.02.002_bib0575","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1038\/sj.cdd.4402081","article-title":"Bcl-2 family proteins are essential for platelet survival","volume":"14","author":"Zhang","year":"2007","journal-title":"Cell Death Differ"},{"key":"10.1016\/j.exphem.2018.02.002_bib0580","doi-asserted-by":"crossref","first-page":"e1593","DOI":"10.1038\/cddis.2014.525","article-title":"MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K\/AKT\/mTOR activation in lymphoid malignancies","volume":"6","author":"Choudhary","year":"2015","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.exphem.2018.02.002_bib0585","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1186\/s12943-015-0460-8","article-title":"miR-377-dependent BCL-xL regulation drives chemotherapeutic resistance in B-cell lymphoid malignancies","volume":"14","author":"Al-Harbi","year":"2015","journal-title":"Mol Cancer"},{"key":"10.1016\/j.exphem.2018.02.002_bib0590","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1111\/bph.13370","article-title":"Bcl-2 phosphorylation confers resistance on chronic lymphocytic leukaemia cells to the BH3 mimetics ABT-737, ABT-263 and ABT-199 by impeding direct binding","volume":"173","author":"Song","year":"2016","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.exphem.2018.02.002_bib0595","doi-asserted-by":"crossref","first-page":"70000","DOI":"10.18632\/oncotarget.12132","article-title":"Acquired resistance to venetoclax (ABT-199) in t (14;18) positive lymphoma cells","volume":"7","author":"Bodo","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.exphem.2018.02.002_bib0600","doi-asserted-by":"crossref","first-page":"4403","DOI":"10.1182\/blood-2008-08-173310","article-title":"Concurrent up-regulation of BCL-XL and BCL2A1 induces approximately 1000-fold resistance to ABT-737 in chronic lymphocytic leukemia","volume":"113","author":"Vogler","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2018.02.002_bib0605","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1182\/blood-2015-12-687814","article-title":"High-content screening identifies kinase inhibitors that overcome venetoclax resistance in activated CLL cells","volume":"128","author":"Oppermann","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2018.02.002_bib0610","doi-asserted-by":"crossref","first-page":"3705","DOI":"10.1158\/1078-0432.CCR-14-2809","article-title":"Pharmacological and protein profiling suggests venetoclax (ABT-199) as optimal partner with ibrutinib in chronic lymphocytic leukemia","volume":"21","author":"Cervantes-Gomez","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.exphem.2018.02.002_bib0615","author":"Hillmen"},{"key":"10.1016\/j.exphem.2018.02.002_bib0620","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1158\/1535-7163.MCT-15-0730","article-title":"Expression profile of BCL-2, BCL-XL, and MCL-1 predicts pharmacological response to the BCL-2 selective antagonist venetoclax in multiple myeloma models","volume":"15","author":"Punnoose","year":"2016","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.exphem.2018.02.002_bib0625","doi-asserted-by":"crossref","first-page":"3192","DOI":"10.1182\/blood-2015-10-675009","article-title":"BCR signaling inhibitors differ in their ability to overcome Mcl-1-mediated resistance of CLL B cells to ABT-199","volume":"127","author":"Bojarczuk","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2018.02.002_bib0630","doi-asserted-by":"crossref","first-page":"16912","DOI":"10.18632\/oncotarget.4857","article-title":"Cyclin E\/Cdk2-dependent phosphorylation of Mcl-1 determines its stability and cellular sensitivity to BH3 mimetics","volume":"6","author":"Choudhary","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.exphem.2018.02.002_bib0635","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1038\/leu.2015.31","article-title":"Dinaciclib is a novel cyclin-dependent kinase inhibitor with significant clinical activity in relapsed and refractory chronic lymphocytic leukemia","volume":"29","author":"Flynn","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2018.02.002_bib0640","doi-asserted-by":"crossref","first-page":"3929","DOI":"10.1182\/blood.V126.23.3929.3929","article-title":"Clinical and correlative results of a phase 1 study of cerdulatinib (PRT062070) a dual SYK\/JAK inhibitor in patients with relapsed\/refractory B cell malignancies","volume":"126","author":"Hamlin","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2018.02.002_bib0645","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1182\/blood-2016-02-700328","article-title":"Dual TORK\/DNA-PK inhibition blocks critical signaling pathways in chronic lymphocytic leukemia","volume":"128","author":"Thijssen","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2018.02.002_bib0650","first-page":"2764","article-title":"Dynamic BH3 profiling reveals novel therapeutic strategies for the treatment of double-hit lymphoma","volume":"130","author":"Crombie","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2018.02.002_bib0655","first-page":"4114","article-title":"Combination of BR101801 and venetoclax demonstrates synergistic activity in DLBCL cell lines harboring double hit and double expressor alterations","volume":"130","author":"Jung","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2018.02.002_bib0660","first-page":"1542","article-title":"Pre-clinical development of targeted therapies for double hit (DH) diffuse large B-cell lymphoma (DLBCL)","volume":"130","author":"Mavis","year":"2017","journal-title":"Blood"}],"container-title":["Experimental Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X18300420?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X18300420?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,6,11]],"date-time":"2022-06-11T01:34:14Z","timestamp":1654911254000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0301472X18300420"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":131,"alternative-id":["S0301472X18300420"],"URL":"https:\/\/doi.org\/10.1016\/j.exphem.2018.02.002","relation":{},"ISSN":["0301-472X"],"issn-type":[{"value":"0301-472X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Venetoclax: A new wave in hematooncology","name":"articletitle","label":"Article Title"},{"value":"Experimental Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.exphem.2018.02.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 ISEH \u2013 Society for Hematology and Stem Cells. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}